Clinical Trial Update: A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD [Phase 3]

View source ↗

Summary

A 6-month extension study to the B2061032 Phase 3 trial is evaluating the safety, tolerability, and efficacy of DVS SR in child and adolescent outpatients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• DVS SR

Snippet

Sponsor: Pfizer | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2016-12-08